The Effects of Aortic Clamping Strategy on Myocardial Protection and Early Postoperative Outcomes During Coronary Artery Bypass Grafting Operations
Aortic Clamping Strategy on Coronary Surgery
DOI:
https://doi.org/10.1532/hsf.3475Keywords:
Myocardial Protection, Ischemia-Reperfusion, Coronary Bypass, BiomarkersAbstract
Background: The purpose of the present study was to compare the effects of two different clamping strategies for the construction of the proximal aortocoronary anastomoses on myocardial protection and postoperative outcomes during coronary artery bypass grafting (CABG) operations.
Methods: In this retrospective study, we examined prospectively collected data of patients who underwent CABG for a 3-year period. Two hundred consecutive patients, who were diagnosed with triple vessel coronary artery disease (CAD), were selected and divided into two groups. In Group 1 (single clamp) (N = 100), venoaortic proximal anastomoses were performed using a single aortic cross-clamp, while in Group 2 (double clamp) (N = 100), proximal anastomoses were performed by using an aortic side clamp. Operative and postoperative outcomes of the patients were compared between the two groups. The serum levels of myocardial damage biomarkers, creatine phosphokinase-MB (CPK-MB), and high sensitive Troponin (hsTnI) results were measured preoperatively, intraoperatively, and postoperatively (6, 12, 24, and 48 hours).
Results: Patient demographics and characteristics were similar between the two groups. In Group 1, cross-clamp duration time (65 min versus 49 min; P = .0001) was longer. However, perfusion time (91 min versus 85 min; P = .61) was similar between the two groups. In Group 2, postoperative CK-MB levels were significantly higher intraoperatively
(P = .18), 6 hours (P = .22), 24 hours (P = .001), and 48 hours (P = .001) than in Group 1. HsTnI was only significantly higher in Group 2 versus Group 1 at 24 hours (P = .001) and 48 hours (P = .01) postoperatively. Time of intensive care unit stay, duration of extubation, and length of hospital stay were similar in both groups.
Conclusion: The technique used for proximal anastomosis has a significant effect on perioperative results, especially on myocardial protection.
References
Adam DH, Filsoufi F, Antmann EM. 2004. Medical management of the patient undergoing cardiac surgery. In: Zipes DP, Libby P, Bonow R, Braunwald E, eds. Braunwald’s heart disease: a textbook of cardiovascular medicine. 7th ed. Philadelphia: WB Saunders; p.1993-2019.
Ali M, Moeen M, Paras I, et al. 2020. Cardio-Protective Effects of Multiport Antegrade Cold Blood Cardioplegia Versus Antegrade Cold Blood Cardioplegia in Patients With Left Ventricular Systolic Dysfunction Undergoing Conventional Coronary Artery Bypass Grafting. Cureus. 12(9): e10308.
Angelini GD, Taylor FC, Reeves BC, et al. 2002. Early and midterm outcome after off-pump and on-pump surgery in beating heart against cardioplegic arrest studies (BHACAS 1 and 2): a pooled analysis of two randomized controlled trials. Lancet. 359:1194-9.
Blauth CI. Macroemboli and microemboli during cardiopulmonary bypass. 1995. Ann Thorac Surg. 59:1300–3.
Buckberg CD. 1979. A proposed solution to the cardioplegic controversy. J Thorac Cardiovasc Surg. 7.
Chowdhury UK, Malik V, Yadav R, et al. 2008. Myocardial injury in coronary artery bypass grafting: On-pump versus off-pump comparison by measuring high-sensitivity C-reactive protein, cardiac troponin I, heart-type fatty acid–binding protein, creatine kinase- MB, and myoglobin release. J Thorac Cardiovasc Surg. 135:1110-9.
Crescenzi G, Cedrati V, Landoni G, et al. 2004. Cardiac biomarker release after CABG with different surgical technique. J Cardiothorac Vasc Anesth. 18:34-7.
D’Ascenzo F, Cavallero E, Moretti C, et al. 2012. Remote ischaemic preconditioning in coronary artery bypass surgery: A Meta-analysis. Heart. 98(17):1267-71.
Daniel 3rd WT, Kilgo P, Puskas JD, et al. 2014. Trends in aortic clamp use during coronary artery bypass surgery: effect of aortic clamping strategies on neurologic outcomes." The Journal of thoracic and cardiovascular surgery. J Thorac Cardiovasc Surg. 147(2):652-7.
Elassal AA, Al-Ebrahim K, Al-Radi O, et al. 2020. Myocardial Protection by Blood-Based Del Nido versus St. Thomas Cardioplegia in Cardiac Surgery for Adults and Children. In The Heart Surg Forum. 23(5):E689-E695.
Erdolu B, As AK, Engin M. 2020. The Relationship between the HATCH Score, Neutrophil to Lymphocyte Ratio and Postoperative Atrial Fibrillation After Off-Pump Coronary Artery Bypass Graft Surgery. Heart Surg Forum 23(1);E088-E092.
Hausenloy DJ, Boston-Griffiths E, Yellon DM. 2012. Cardioprotection during cardiac surgery. Cardiovasc Res. 94(2):253–65.
Jelodar G, Zarrabi K, Nazifi S, et al. 2017. Comparison of Serum Myocardial Biomarkers Following Two Different Methods of Venoaortic Connection in Coronary Artery Bypass Grafting: A Randomized Clinical Trial. Zahedan J Res Med Sci. 19(7):e10740.
Jørgensen PH, Nybo M, Jensen MK, et al. 2014. Optimal cut-off value for cardiac troponin I in ruling out type 5 myocardial infarction. Interact Cardiovasc Thorac Surg. 18:544–550.
Khouri SF, Warner KG, Butler M, et al. 1988. The superiority of continuous cold blood cardioplegia in the metabolic protection of the hypertrophied human heart. J Thorac Cardiovasc Surg. 95(3):442-54.
Mills SA. Cerebral injury and cardiac operations. 1993. Ann Thorac Surg. 56:S86 –91.
Pegg TJ, Maunsell Z, Karamitsos TD, et al. 2011. Utility of cardiac biomarkers for the diagnosis of type V myocardial infarction after coronary artery bypass grafting: Insights from serial cardiac MRI. Heart. 97:810–816.
Rahimi K, Banning AP, Cheng AS, et al. 2009. Prognostic value of coronary revascularisation-related myocardial injury: A cardiac magnetic resonance imaging study. Heart. 95:1937–1943.
Ram H, Dwarakanath S, Green AE, et al. 2020. Iatrogenic aortic dissection associated with cardiac surgery: A narrative review. Journal of Cardiothoracic and Vascular Anesthesia. Online ahead of print.
Sanjay OP, Srikrishna SV, Prashanth P, et al. 2003. Antegrade versus antegrade with retrograde delivery of cardioplegic solution inmyocardial revascularisation. A clinical study in patients with triple vessel coronary artery disease. Ann Card Anaesth. 6(2):143– 8.
Scarsini R, Zivelonghi C, Pesarini G, et al. 2016. Repeat revascularization: percutaneous coronary intervention after coronary artery bypass graft surgery. Cardiovascular Revascularization Medicine. 17(4):272-278.
Sirvinskas E, Kinderyte A, Trumbeckaite S, et al. 2015. Effects of sevoflurane vs. propofol on mitochondrial functional activity after ischemia-reperfusion injury and the influence on clinical parameters in patients undergoing CABG surgery with cardiopulmonary bypass. Perfusion. 30:590–595.
Sobral MLP, Santos GG, Santos LAS, et al. 2006. Comparative randomized study of the immediate outcomes of patients with radial arteries proximally anastomosed to the aorta or as a composite graft. Rev Bras Cir Cardiovasc. 21(1):35-41.
Thielmann M, Sharma V, Al-Attar N, et al. 2017. ESC Joint Working Groups on Cardiovascular Surgery and the Cellular Biology of the Heart Position Paper: Peri-operative myocardial injury and infarction in patients undergoing coronary artery bypass graft surgery. Eur Heart J. 38:2392–2411.
Turer AT, Hill JA. 2010. Pathogenesis of myocardial ischemia-reperfusion injury and rationale for therapy. Am J Cardiol. 106(3):360–8.
Ucak HA, Uncu H. 2019. Impact of Coronary Collateral Circulation of Perioperative Myocardial Damage in High-Risk Patients Undergoing Coronary Artery Bypass Grafting Surgery. Heart Surg Forum. 11;22(5):E375-E379.
Zakkar M, Guida G, Suleiman MS, et al. 2015. Cardiopulmonary bypass and oxidative stress. Oxid Med Cell Longev. 2015:189863.
Published
How to Cite
Issue
Section
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).
